• Aleksandar Tomašević 1Institute for oncology and radiology of Serbia, Pasterova 14, Belgrade, Serbia 2Faculty of Medicine, University of Belgrade, Dr. Subotića 8, Belgrade, Serbia
  • Mira Karadžić Institut za onkologiju i radiologiju Srbije, Beograd
  • Mirjana Miković Institut za onkologiju i radiologiju Srbije, Beograd
  • Vesna Veković Medicinski fakultet Univerziteta u Beogradu, Beograd
  • Milena Tomašević Zavod za zdravstvenu zaštitu studenata Beogradskog Univerziteta, Beograd




cervical cancer, youth, prevention, vaccination


In addition to developed prevention and modern, successful treatment modalities, cervical cancer still represents a major social and epidemiological problem in the world, especially in underdeveloped and developing countries. According to the cervical cancer incidence and mortality, Serbia has been at the top of the list of European countries for decades.

The proven central role of chronic HPV infection and the persistent presence of viral DNK in the genetic material of the cells of the cervical mucosa has led to the development of successful prevention measures.

Primary prevention is presented through HPV immunization of the population in childhood/early adolescence. Secondary prevention is presented through screening to detect asymptomatic premalignant changes or early stages of invasive disease.

It has been shown that the population benefit from vaccination is achieved when the level of immunization exceeds 50%. In Serbia, the nine-valent HPV vaccine is currently available, although the vaccination itself is not mandatory but at the level of recommendation, which with insufficient information about HPV infection, combined with the already widespread negative opinion towards vaccination in general, results in a low overall percentage. Also, there is still no adequately developed organized screening, it is most often carried out as opportune screening, based on colposcopy with PAP testing, while HPV testing is carried out on a much smaller scale, all of which represent the reasons for the high incidence and mortality from cervical cancer in Serbia.


Globacan 2020. Available: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf.

Miljus D, Zivkovic Perisic S, Bozic Z, editors. Malignant tumours in republic of Serbia 2019. Institute of Public Health of Serbia. Department for Prevention and Control of Noncommunicable Diseases, Serbia. ISBN 978-86-7358-111-8.

Manini I, Montomoli E. Epidemiology and prevention of Human Papillomavirus. Ann Ig. 2018;30 (4 Suppl 1):28-32.

Moscicki AB, Burt VG, Kanowitz S, Darragh T, Shiboski S. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer. 1999; 85 (5):1139-1144.

Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013; 178 (7):1161-1169.

Van Doorslaer K, Burk RD. Evolution of human papillomavirus carcinogenicity. Adv Virus Res. 2010; 77:41-62.

Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020; 32 (6):720-728.

Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020; 247:163-175.

Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161-e9.

Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. ISBN 978-92-4-001410-7

Oliveira CR, Niccolai LM. Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination. Prev Med. 2021;144:106363.

Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293-1302.

World Health Organization, Human papillomavirus vaccines: WHO position paper (2022 update). Weekly Epidemioogical record, No 50, 16 December 2022; 645-672.

Purrinos-Hermida MJ, Santiago-Perez MI, Trevino M, Dopazo R, Canizares A, Bonacho I, et al. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. PLoS One. 2018;13(8):e0201653.

Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, et al. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016. J Infect Dis. 2018;218(6):911-921.

Falcaro M, Castanon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084-2092.

Castle PE, Xie X, Xue X, Poitras NE, Lorey TS, Kinney WK, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med. 2019; 118:44-50.

Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698-702.

Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497-509.

Ministry of Health of the Republic Serbia. Zakon o zaštiti stanovništva od zaraznih bolesti: 15/2016-31, 68/2020-4, 136/2020-3. (cited 16 Jan 2023). Available: https://www.pravno-informacioni-sistem.rs/SlGlasnikPortal/eli/rep/sgrs/skupstina/zakon/2016/15/8/reg.

Sundstrom B, Cartmell KB, White AA, Russo N, Well H, Pierce JY, et al. HPV Vaccination Champions: Evaluating a Technology-Mediated Intervention for Parents. Front Digit Health. 2021;3:636161.

Maric G, Bircanin D, Kisic V, Dotlic J, Zaric M, Kisic-Tepavcevic D, et al. Parental perspective on human papillomavirus (HPV) vaccination in Serbia: Knowledge, attitudes and practice. Sex Reprod Healthc. 2018;16:192-198.

Strbac M, Vukovic V, Pustahija T, Nikolic N, Rajcevic S, Ilic S, et al. Motives and attitudes of parents toward HPV vaccination: Results from the initial period of HPV vaccine rollout in Serbia. PLoS One. 2023;18(7):e0287295.

Rancic NK, Golubovic MB, Ilic MV, Ignjatovic AS, Zivadinovic RM, Denic SN, et al. Knowledge about Cervical Cancer and Awareness of Human Papillomavirus (HPV) and HPV Vaccine among Female Students from Serbia. Medicina (Kaunas). 2020;56(8).

Force USPST, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674-686.

Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, et al. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study. Ann Intern Med. 2018;168(1):20-29.

Austin RM, Onisko A, Zhao C. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting. Am J Clin Pathol. 2018;150(5):385-392.






Review Articles